Etoricoxib is a selective cyclooxygenase-2 inhibitor used to treat acute gout and osteoarthritis. It reduces inflammation by blocking the cox-2 enzyme, which is responsible for producing prostaglandins. The medication specifically targets pain and swelling in joints while sparing normal tissue. By inhibiting cox-2, it decreases the synthesis of inflammatory mediators that cause redness and tenderness. This targeted action helps improve mobility and comfort for patients with rheumatic conditions. It is taken orally and works systemically throughout the body to provide therapeutic benefit.

Etoricoxib is a selective inhibitor of the cyclooxygenase 2 enzyme used in clinical practice. It belongs to the class of nonsteroidal antiinflammatory drugs formulated for oral administration. The drug is primarily prescribed to relieve symptoms of rheumatoid arthritis and osteoarthritis. It is also indicated for the acute treatment of gouty arthritis and for the long term management of chronic musculoskeletal pain. Pharmacologically Etoricoxib binds selectively to the cox 2 catalytic site reducing the production of prostaglandins involved in inflammation. By decreasing these inflammatory mediators it helps to lower pain swelling and fever in affected joints. Its inhibition of cox 2 spares the cox 1 enzyme in the gastrointestinal tract leading to a comparatively favorable gastrointestinal safety profile. This targeted mechanism allows the medication to provide therapeutic benefit with a lower risk of certain gastrointestinal complications.

Fatigue is a frequently reported symptom across many treatments. Headache often occurs as a mild and temporary effect. Nausea can appear during the initial adjustment period. Dizziness may be experienced by some individuals without lasting consequences. Itching sometimes develops as a skin reaction that is usually short lived. Mild fever is occasionally observed without serious implications. Skin rash can appear as a common but manageable response.

The most common side effects are usually mild, such as localized redness at the injection site. They may also include temporary headache or low grade fever. Some people experience short term fatigue that resolves within a day or two. Mild muscle aches and occasional chills are also reported. These reactions are generally short lived and indicate normal immune activation. Serious adverse events are rare and not part of this typical pattern.